Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06168409 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 218
- Enrollment target
NCT06168409 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 218 participants.
The verdict
NCT06168409, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 218 participants
- Enrollment target
Study Summary
This is a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety, tolerability and the effect of 2 mg Baxdrostat vs. placebo, administered QD orally, on the reduction of SBP, measured by average 24-hour ABPM in 212 participants with rHTN (defined as seated SBP ≥ 140 mmHg at Screening and mean ambulatory SBP ≥ 130 mmHg at baseline, despite a stable regimen of ≥ 3 antihypertensive agents, one of which is a diuretic).
Interventions
- DRUG Placebo
- DRUG Baxdrostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2025-08-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06168409
The ClinicalTrials.gov registry entry for NCT06168409 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 218 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06168409 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06168409 about?
NCT06168409 is a clinical study titled "A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension". This is a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety, tolerability and the effect of 2 mg Baxdrostat vs. placebo, administered QD orally, on the reduction of SBP, measured by average 24-hour ABPM in 212 participants with rHTN (de...
What is the current status of trial NCT06168409?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 218 participants. The study started on 2024-03-01. Estimated completion is 2025-08-17.
What interventions are being tested in trial NCT06168409?
The interventions under investigation include: Placebo (DRUG), Baxdrostat (DRUG).
Who is sponsoring clinical trial NCT06168409?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.